Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan

Medical University of South Carolina40 enrolled

Overview

The purpose of this study is to evaluate contrast media volume, safety and 30-day outcome of patients after a computed tomography (CT) scan. The results of this study will help to determine the minimum volume of contrast material that can be used to ensure patient safety while not compromising diagnostic image quality in high-risk patients.

The scholarly rationale for the study is to determine the feasibility of restricting the contrast media volume to 60ml of 270mg Iodine (mgI)/ml iodixanol or less to accomplish sufficient intravascular attenuation for comprehensive CT assessment prior to TAVR. The study will also evaluate the effects of contrast media administration on our subjects' kidney function by performing serum creatinine measurements at baseline, as well as at three days and thirty days after contrast media administration.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Aortic Valve Stenosis

Interventions

Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scanDRUG

An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject must be 18-90 years of age. 2. Subject must have been referred for a clinically indicated CT prior to TAVR. 3. Subject must provide written informed consent prior to any study-related procedures being performed. 4. Subject must be willing to comply with all clinical study procedures. Exclusion Criteria: 1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy: * By testing (serum or urine βHCG) within 24 hours before contrast agent administration, or * By surgical sterilization, or * Post menopausal, with minimum one (1) year history without menses. 2. Subject has an acute psychiatric disorder or is cognitively impaired. 3. Subject is using or is dependent on substances of abuse. 4. Subject is unwilling to comply with the requirements of the protocol. 5. Subject has previously entered this study. 6. Subject has an allergy against iodinated contrast agents. 7. Subject is in acute unstable condition.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Clinically Diagnostic CT Assessments

Determine that restricting the contrast media volume to 60ml of 270 mgI/ml iodixanol or less generates clinically diagnostic CT assessments prior to TAVR.

Time frame: up to 2 years

Secondary Outcomes

Image Quality

Measure contrast media attenuation and determine diagnostic image quality within target structures in the aortic root and the ilio-aortic access route.

Time frame: up to 2 years

Safety

Evaluate safety and 30-day outcome of patients regarding survival, renal function, and adverse events (renal failure, dialysis, general morbidity).

Time frame: up to 2 years

Long-term Follow-Up

Determine procedural outcome of the TAVR procedure by longer-term patient follow-up after one and two years for device function, position, and paravalvular leakage.

Time frame: up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.